NEW YORK (GenomeWeb News) – Murex Pharmaceuticals licensed from Ariadne Genomics its Pathway Studio software to help develop cancer therapeutics, Ariadne said yesterday.
Murex will use Pathway Studio to develop computer-based models to identify and validate cancer targets.

Financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.